News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)